Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 361 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bladder, Overactive Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Over Active Bladder Patients Having Sling Surgery

NCT00852696
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solifenacin, Placebo
Drug · Other
Lead sponsor
Cleveland Clinic Florida
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 22, 2026, 11:21 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00439140
View directory record Official record
Conditions
Overactive Bladder
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 22, 2026, 11:21 AM EDT
Terminated Phase 2 Interventional

Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients

NCT00332319
View directory record Official record
Conditions
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Long Beach, California • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 4 Interventional

Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women

NCT00143481
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
58
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 22, 2026, 11:21 AM EDT
Terminated Phase 3 Interventional Results available

Over Active Bladder Instillation Study - Botox

NCT00667095
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Urge Incontinence
Interventions
Botox Instillation, DMSO Instillation
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder

NCT01369485
View directory record Official record
Conditions
Overactive Bladder
Interventions
(VERV™ System), Sham version of (VERV™ System)
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Tucson, Arizona • Murrieta, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 22, 2026, 11:21 AM EDT
Terminated Phase 2 Interventional Results available

A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

NCT00712322
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Darifenacin
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
2 Years to 15 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
9
States / cities
San Diego, California • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 22, 2026, 11:21 AM EDT
Completed No phase listed Observational

Deep Brain Stimulation in Patients With LUTS

NCT03202251
View directory record Official record
Conditions
Bladder Dysfunction, Neurogenic Bladder
Interventions
It's is a cohort
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 22, 2026, 11:21 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity

NCT00495053
View directory record Official record
Conditions
Overactive Bladder
Interventions
hMaxi-K, Placebo
Drug · Other
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Branford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 22, 2026, 11:21 AM EDT
Not yet recruiting Phase 3 Interventional

Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder

NCT07780786
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Wearable neurostimulation system for saphenous nerve stimulation, tolterodine tartrate 4 mg extended release
Device · Drug
Lead sponsor
NinaMED Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 11:21 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.

NCT00323635
View directory record Official record
Conditions
Urinary Incontinence
Interventions
tolterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Mirabegron For Erectile Dysfunction

NCT02916693
View directory record Official record
Conditions
Erectile Dysfunction, Overactive Bladder, Urinary Incontinence
Interventions
Mirabegron
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 22, 2026, 11:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Antibiotic Usage Prior to OnabotulinumtoxinA Injection

NCT04754737
View directory record Official record
Conditions
Antibiotic Stewardship, Overactive Bladder, Onabotulinumtoxin A, UTI
Interventions
No antibiotic, Prophylactic antibiotic, cystoscopic injection of onabotulinumtoxinA
Other · Procedure
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 22, 2026, 11:21 AM EDT
Withdrawn Not applicable Interventional

Noninvasive Spinal Cord Stimulation for Neurogenic and Idiopathic Overactive Bladder

NCT03753750
View directory record Official record
Conditions
Overactive Bladder, Incontinence, Urge, Neurogenic Bladder
Interventions
Noninvasive spinal cord stimulation
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 22, 2026, 11:21 AM EDT
Terminated Phase 4 Interventional Results available

Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate

NCT01605617
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine fumarate, Placebo, Percutaneous Tibial Nerve Stimulation (PTNS)
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Oct 22, 2026, 11:21 AM EDT
Recruiting Not applicable Interventional

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women

NCT07209397
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant), Mixed Urinary Incontinence, Idiopathic Overactive Bladder With Urinary Incontinence, Idiopathic Overactive Bladder
Interventions
Detrusor nerve radiofrequency ablation, Simulated (sham) detrusor nerve radiofrequency ablation
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
22 Years to 80 Years · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 22, 2026, 11:21 AM EDT
Withdrawn Phase 2 Interventional

Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.

NCT00262496
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
Botox
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Animated Videos to Foster Healthy Bladder Behaviors in Community Women

NCT06921915
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence, Urge
Interventions
eLearning
Other
Lead sponsor
Kathleen O'Connell
Other
Eligibility
40 Years to 64 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 22, 2026, 11:21 AM EDT
Completed No phase listed Observational

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT02386072
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
Interventions
mirabegron, antimuscarinic medication
Drug
Lead sponsor
Astellas Scientific & Medical Affairs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 22, 2026, 11:21 AM EDT
Terminated Phase 3 Interventional Results available

Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder

NCT00821184
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vesicare (solifenacin), Vesicare (solifenacin) plus behavioral modification
Drug · Behavioral
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

NCT00914667
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
warfarin, Warfarin plus Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Oct 22, 2026, 11:21 AM EDT
Completed No phase listed Observational

A Cost Analysis of Interstim Therapy

NCT00200031
View directory record Official record
Conditions
Urinary Retention and Symptoms of Overactive Bladder (Urge, Frequency)
Interventions
Interstim therapy
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2008 · Synced Oct 22, 2026, 11:21 AM EDT
Recruiting Not applicable Interventional

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

NCT07195656
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Device Group, Medication Group
Device · Drug
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Beverly Hills, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 11:21 AM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 11:21 AM EDT